SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · Biogen announced the acquisition of private biotech RayThera for up to…

Biogen Inc. · PRESS-RELEASE filed Jun 17, 2026 at 18:59 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 17, 2026 at 18:59 ET

Biogen announced the acquisition of private biotech RayThera for up to $1 billion (upfront plus milestone payments), adding early-stage small-molecule immunology assets. The lead candidate is expected to enter Phase 1 in Q3 2026, and the deal is anticipated to close in Q3 2026. At ~3.5% of Biogen's market cap, this is a modest bolt-on pipeline expansion with no near-term revenue impact.

  • Total potential deal value up to $1 billion, consisting of upfront payment and clinical/regulatory milestone payments
  • RayThera's lead candidate expected to enter Phase 1 development in early Q3 2026
  • Transaction expected to close in Q3 2026, subject to customary conditions and regulatory approvals
  • RayThera is a private San Diego-based small molecule immunology company that recently completed a Series A financing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access